ATE488526T1 - Chimärer impfstoff für haemophilus influenzae- induzierte infektion - Google Patents

Chimärer impfstoff für haemophilus influenzae- induzierte infektion

Info

Publication number
ATE488526T1
ATE488526T1 AT06800001T AT06800001T ATE488526T1 AT E488526 T1 ATE488526 T1 AT E488526T1 AT 06800001 T AT06800001 T AT 06800001T AT 06800001 T AT06800001 T AT 06800001T AT E488526 T1 ATE488526 T1 AT E488526T1
Authority
AT
Austria
Prior art keywords
haemophilus influenzae
protein
chimeric vaccine
induced infection
nthi
Prior art date
Application number
AT06800001T
Other languages
German (de)
English (en)
Inventor
Lauren Bakaletz
Robert Munson
Original Assignee
Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital filed Critical Nationwide Childrens Hospital
Application granted granted Critical
Publication of ATE488526T1 publication Critical patent/ATE488526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06800001T 2005-07-08 2006-07-05 Chimärer impfstoff für haemophilus influenzae- induzierte infektion ATE488526T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69764205P 2005-07-08 2005-07-08
US80183506P 2006-05-19 2006-05-19
PCT/US2006/026183 WO2007008527A2 (en) 2005-07-08 2006-07-05 Chimeric vaccine for haemophilus influenzae-induced disease

Publications (1)

Publication Number Publication Date
ATE488526T1 true ATE488526T1 (de) 2010-12-15

Family

ID=37441871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800001T ATE488526T1 (de) 2005-07-08 2006-07-05 Chimärer impfstoff für haemophilus influenzae- induzierte infektion

Country Status (7)

Country Link
US (3) US7811591B2 (https=)
EP (2) EP2298794A3 (https=)
JP (2) JP2009500037A (https=)
AT (1) ATE488526T1 (https=)
CA (1) CA2613970C (https=)
DE (1) DE602006018308D1 (https=)
WO (1) WO2007008527A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP2015534964A (ja) * 2012-10-17 2015-12-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US9855326B2 (en) 2013-03-08 2018-01-02 Research Institute At Nationwide Children's Hospital Transcutaneous haemophilus influenzae vaccine formulations and methods
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
SG11202103001PA (en) 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19005A (en) 1857-12-29 de witt
US697642A (en) 1901-03-09 1902-04-15 Liberty Millet Process of strengthening clay hydraulic pipe, vases, crockery-ware, &c.
US801835A (en) 1905-02-25 1905-10-17 Rudolph H Apelt Ball-bearing.
US1900504A (en) 1930-11-25 1933-03-07 Ingersoll Rand Co Condensing apparatus
ES2185658T3 (es) * 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
PL1697403T3 (pl) * 2003-12-23 2010-09-30 Nationwide Childrens Hospital Inc Pilusy typu IV Haemophilus influenzae
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion

Also Published As

Publication number Publication date
WO2007008527A2 (en) 2007-01-18
EP1904519B1 (en) 2010-11-17
JP2009500037A (ja) 2009-01-08
EP2298794A2 (en) 2011-03-23
US20130064828A1 (en) 2013-03-14
US20080311110A1 (en) 2008-12-18
JP2010172332A (ja) 2010-08-12
US20110081357A1 (en) 2011-04-07
US8263363B2 (en) 2012-09-11
EP1904519A2 (en) 2008-04-02
WO2007008527A3 (en) 2007-03-15
DE602006018308D1 (de) 2010-12-30
US8741304B2 (en) 2014-06-03
CA2613970A1 (en) 2007-01-18
US7811591B2 (en) 2010-10-12
CA2613970C (en) 2015-12-08
EP2298794A3 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
ATE488526T1 (de) Chimärer impfstoff für haemophilus influenzae- induzierte infektion
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
WO2004030608A3 (en) Nanoemulsion vaccines
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
EA200801907A1 (ru) Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью, иммуногенная композиция агониста tlr-3 и вектора экспрессии гетерологичного белка, способ индукции иммунного ответа с помощью агониста tlr-3 и вектора экспрессии гетерологичного белка и выделенная нуклеиновая кислота
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
ATE318899T1 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
DK1929047T3 (da) Fremgangsmåder og sammensætninger til vaccination af dyr med PRRSV-antigener med forbedret immunogenicitet
DE60239594D1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
NO20054608L (no) Influensavirusvaksine
SG169375A1 (en) Yeast-based vaccine for inducing an immune response
EP1399181A4 (en) PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCUS
MA30581B1 (fr) Vaccin viral recombinant
WO2008002663A3 (en) Immunogenic protein constructs
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
NO20081043L (no) Vaksine for fisk
ATE461710T1 (de) Nipah-virus-impfstoffe
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
NZ760789A (en) Uti fusion proteins
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
DK1724342T3 (da) Fremgangsmåde til fremstilling af Erysipelothrix rhusiopathiae overfladebeskyttende antigenmutant i Escherichia coli
WO2013171661A3 (en) Adjuvant formulations and methods
WO2007120860A3 (en) Nanoemulsion vaccines
WO2006007366A3 (en) SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties